PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-2.48%
Revenue decline while CRON.TO shows 30.63% growth. Joel Greenblatt would examine competitive position erosion.
2.66%
Cost increase while CRON.TO reduces costs. John Neff would investigate competitive disadvantage.
-18.23%
Gross profit decline while CRON.TO shows 95.38% growth. Joel Greenblatt would examine competitive position.
-16.16%
Margin decline while CRON.TO shows 96.46% expansion. Joel Greenblatt would examine competitive position.
-42.29%
R&D reduction while CRON.TO shows 24.50% growth. Joel Greenblatt would examine competitive risk.
53.56%
G&A growth 1.25-1.5x CRON.TO's 40.95%. Martin Whitman would scrutinize overhead control.
-7.15%
Both companies reducing marketing spend. Martin Whitman would check industry trends.
-231.01%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
49.13%
Operating expenses growth above 1.5x CRON.TO's 20.99%. Michael Burry would check for inefficiency.
18.08%
Total costs growth while CRON.TO reduces costs. John Neff would investigate differences.
64.38%
Interest expense change of 64.38% while CRON.TO maintains costs. Bruce Berkowitz would investigate control.
-9.04%
D&A reduction while CRON.TO shows 22.66% growth. Joel Greenblatt would examine efficiency.
-6043.79%
EBITDA decline while CRON.TO shows 9.21% growth. Joel Greenblatt would examine position.
64.56%
EBITDA margin growth exceeding 1.5x CRON.TO's 30.41%. David Dodd would verify competitive advantages.
-61.11%
Operating income decline while CRON.TO shows 6.32% growth. Joel Greenblatt would examine position.
-65.20%
Operating margin decline while CRON.TO shows 28.28% growth. Joel Greenblatt would examine position.
-194.63%
Other expenses reduction while CRON.TO shows 225.57% growth. Joel Greenblatt would examine advantage.
-159.99%
Pre-tax income decline while CRON.TO shows 35.04% growth. Joel Greenblatt would examine position.
-166.59%
Pre-tax margin decline while CRON.TO shows 3.37% growth. Joel Greenblatt would examine position.
133.92%
Tax expense growth 1.25-1.5x CRON.TO's 99.86%. Martin Whitman would scrutinize strategy.
-205.02%
Net income decline while CRON.TO shows 36.57% growth. Joel Greenblatt would examine position.
-212.77%
Net margin decline while CRON.TO shows 4.54% growth. Joel Greenblatt would examine position.
-181.58%
EPS decline while CRON.TO shows 40.00% growth. Joel Greenblatt would examine position.
-181.58%
Diluted EPS decline while CRON.TO shows 40.00% growth. Joel Greenblatt would examine position.
9.00%
Share count reduction below 50% of CRON.TO's 0.20%. Michael Burry would check for concerns.
9.00%
Diluted share reduction below 50% of CRON.TO's 1.06%. Michael Burry would check for concerns.